Modern neurology has shifted the treatment of migraines from antiquated remedies like blood-letting to targeted biological therapies. According to Alexandra Sinclair, a professor of neurology at the University of Birmingham and chair of the British Association for the Study of Headache, medical consensus now classifies migraines as a primary neurological disorder caused by the activation of the trigeminovascular system, which triggers the release of the pain-signaling chemical CGRP.
Understanding the Trigeminal Nerve and CGRP
The core of the migraine mechanism lies in the trigeminal nerve, the largest and most complex sensory nerve in the head. When this nerve system is activated, it releases calcitonin gene-related peptide (CGRP), a chemical that activates the brain’s pain network and causes headaches that range from moderate to crippling. Professor Alexandra Sinclair of the University of Birmingham notes that this discovery has fundamentally changed how physicians approach diagnosis and treatment.
Unlike secondary headaches, which arise from structural issues like tumors or meningitis, migraines are primary headaches. They often present with severe, pounding pain, typically on one side of the head, and are frequently accompanied by nausea and sensitivity to light or sound.
Did you know?
Migraines occur in four distinct phases: the prodrome (warning period), the aura (visual or sensory disturbances), the headache itself, and the postdrome (the “washout” phase). Symptoms such as yawning or food cravings during the prodrome are now understood to be symptoms of the migraine itself, rather than triggers.
The Evolution of Migraine Treatment
For centuries, migraine management was plagued by misconceptions. Historical records, such as the Ebers Papyrus from 1550 BC, suggest primitive attempts at relief, while 20th-century medicine often misattributed the condition to repressed emotions or “neurotic” behavior in women. The “vascular theory,” which posited that expanding and contracting blood vessels caused the pain, remained the standard teaching in medical schools until only a few decades ago.
Today, the focus has shifted to CGRP inhibitors. These include:
- Gepants: Oral medications that block the CGRP receptor.
- Monoclonal Antibodies (Mabs): Monthly injections designed to block the CGRP protein.
While these therapies have revolutionized care over the last four or five years, Prof. Sinclair highlights that access remains a significant barrier due to high costs and a shortage of specialized headache management services.
Managing Triggers and Daily Life
While genetics play a major role in susceptibility, lifestyle factors can influence the frequency of attacks. Dehydration, irregular sleep patterns, caffeine withdrawal, and stress are established contributors to migraine onset. However, the link between screen time and migraines remains scientifically debated, despite common perceptions.
Frequently Asked Questions
Why do women experience more migraines than men?
According to Prof. Sinclair, the disparity is linked to hormonal differences and variations in how individual brains respond to pain-signaling chemicals.
Are food cravings a trigger for migraines?
Research suggests the opposite. Functional brain imaging shows that the brain areas responsible for food cravings activate up to 24 hours before the pain begins, meaning the migraine causes the craving rather than the food causing the migraine.
Is a migraine a “real” medical condition?
Yes. The World Health Organization lists migraine in the top 10 most disabling diseases globally, affecting productivity for many during their prime working years.
Worth a look